-
公开(公告)号:US11905285B2
公开(公告)日:2024-02-20
申请号:US17519013
申请日:2021-11-04
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jeremy Travins , Thomas Miller , Nikolaos Papaioannou
IPC: C07D471/04 , C07D417/04 , C07D417/14
CPC classification number: C07D471/04 , C07D417/04 , C07D417/14
Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
-
公开(公告)号:US11903900B2
公开(公告)日:2024-02-20
申请号:US17282132
申请日:2019-09-24
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Seth Dale Jones , Madeleine Clare Gibson , Denise A. Alexander , Daniel Edward Roush
CPC classification number: A61J1/16 , A61J1/1412 , A61J1/1493 , B65D71/50
Abstract: A container unit may be used to facilitate administrations of multiple medicinal fluids to a patient. A container unit may include a first container, a second container, and a carrier which holds the first container and the second container stationary relative to each other. The carrier may include a lip configured to engage a pooling device to secure the container unit to the pooling device. The carrier may also include a slot configured to engage an insert on the pooling device to guide the container unit as the container unit is secured to the pooling device. The carrier may also include a first portion and second portion with different shapes that are complementary to a shape of a port on the pooling device. The carrier may also include an extension which extends in a direction away from one of the first container to a level at least even with a stopper disposed in the first container. The container unit may include a lid including at least one rotation inhibitor configured to inhibit rotation of the lid about at least one axis. A plurality of container units may include container units having different volume containers while maintaining a congruent interface portions.
-
公开(公告)号:US20240043817A1
公开(公告)日:2024-02-08
申请号:US18052442
申请日:2022-11-03
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Dave Nichols
CPC classification number: C12N9/16 , A61K38/465 , C12Y301/06013
Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
-
公开(公告)号:US11892450B2
公开(公告)日:2024-02-06
申请号:US16881911
申请日:2020-05-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Kusumam Joseph , Allen P. Kaplan
IPC: G01N33/53 , G01N33/573 , C12Q1/37 , G01N33/68 , C07K16/38 , C07K14/435 , C07K16/40
CPC classification number: G01N33/573 , C07K14/435 , C07K16/38 , C07K16/40 , C12Q1/37 , G01N33/6893 , C07K2317/21 , C07K2317/76 , G01N2333/4706 , G01N2333/8121 , G01N2333/96455 , G01N2333/96458 , G01N2800/32 , G01N2800/52 , G01N2800/70
Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
-
公开(公告)号:USD1012092S1
公开(公告)日:2024-01-23
申请号:US29756270
申请日:2020-10-27
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Designer: McCay Barnes , Veronika Nowak
Abstract: FIG. 1 is a first image in a sequence for a display screen with a transitional graphical user interface showing the first embodiment of the new design;
FIG. 2 is the second image thereof;
FIG. 3 is the third image thereof;
FIG. 4 is the fourth image thereof;
FIG. 5 is the fifth image thereof;
FIG. 6 is the sixth image thereof;
FIG. 7 is the seventh image thereof;
FIG. 8 is the eighth image thereof;
FIG. 9 is the ninth image thereof;
FIG. 10 is the first image in a sequence for a display screen with a transitional graphical user interface showing the second embodiment of the new design;
FIG. 11 is the second image thereof;
FIG. 12 is the third image thereof;
FIG. 13 is the fourth image thereof;
FIG. 14 is the fifth image thereof;
FIG. 15 is the sixth image thereof;
FIG. 16 is the seventh image thereof;
FIG. 17 is the eighth image thereof;
FIG. 18 is the ninth thereof;
FIG. 19 is the first image in a sequence for a display screen with a transitional graphical user interface showing the third embodiment of the new design;
FIG. 20 is the second image thereof;
FIG. 21 is the third image thereof;
FIG. 22 is the fourth image thereof;
FIG. 23 is the fifth image thereof;
FIG. 24 is the sixth image thereof;
FIG. 25 is the seventh image thereof;
FIG. 26 is the eighth image thereof; and,
FIG. 27 is the ninth image thereof.
The broken-line rectangle illustrates the perimeter of a display screen. The remaining broken lines illustrate portions of the transitional graphical user interface. The broken lines form no part of the claimed design. The appearance of the image transitions sequentially between the images shown in FIGS. 1-9, FIGS. 10-18, and FIGS. 19-27, respectively. The process or period in which an image transitions to another forms no part of the claimed design.-
公开(公告)号:US11857575B2
公开(公告)日:2024-01-02
申请号:US15772668
申请日:2016-11-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Olga De La Rosa , Eleuterio Lombardo , Wilfried Dalemans , Javier Garcia Casado , Rebeca Blazquez Duran , Francisco Miguel Sanchez Margallo
IPC: A61K35/02 , A61K9/127 , A61K9/50 , C12N15/62 , A61P29/00 , A61P37/06 , A61K45/06 , A61K35/35 , A61K31/519 , A61K31/4709 , A61K31/444 , A61K31/4439 , A61K31/5377 , G01N1/40 , C12N5/0775 , A61K35/12 , A61K35/28
CPC classification number: A61K35/28 , A61K9/127 , A61K9/5068 , A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/519 , A61K31/5377 , A61K35/35 , A61K45/06 , A61P29/00 , A61P37/06 , C12N15/625 , A61K2035/122 , A61K2035/128 , A61K2300/00 , C12N5/0667 , G01N1/4077 , A61K31/4709 , A61K2300/00 , A61K31/5377 , A61K2300/00 , A61K31/4439 , A61K2300/00 , A61K31/444 , A61K2300/00 , A61K31/519 , A61K2300/00 , A61K35/28 , A61K2300/00
Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
-
47.
公开(公告)号:US11851481B2
公开(公告)日:2023-12-26
申请号:US17121553
申请日:2020-12-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor: William H. Frey, II , Leah Ranae Bresin Hanson , Sharon Pokropinski , Francisco M. Rausa, III
IPC: C07K16/18 , A61K9/00 , C07K16/06 , A61K9/08 , A61K31/4172 , A61K31/401 , A61K31/198 , A61K39/00
CPC classification number: C07K16/18 , A61K9/0043 , A61K31/401 , A61K31/4172 , C07K16/06 , A61K9/08 , A61K31/198 , A61K2039/505 , A61K2039/543 , C07K2317/21 , C07K2317/55 , C07K2317/92
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
-
48.
公开(公告)号:US20230408528A1
公开(公告)日:2023-12-21
申请号:US18308813
申请日:2023-04-28
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jiang Wu , Guodong Zhang , Daniel J. Sexton , Ryan Faucette , Gul M. Mustafa , Mark Szewc
CPC classification number: G01N33/6848 , G01N30/7233 , G01N30/88 , G01N33/6893 , G01N2030/027
Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
-
公开(公告)号:US20230399356A1
公开(公告)日:2023-12-14
申请号:US18336436
申请日:2023-06-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor: He XU , Hong Myung LEE , Christopher ARENDT
IPC: C07H21/00 , A61K47/68 , A61P35/00 , A61K31/7084
CPC classification number: C07H21/00 , A61K47/6849 , A61P35/00 , A61K31/7084 , A61K47/6889
Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.
-
公开(公告)号:US20230395254A1
公开(公告)日:2023-12-07
申请号:US18006967
申请日:2021-07-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jordan Brayanov , Cristina Menchero Almansa , Meena Subramanyam
IPC: G16H50/20 , G16H20/17 , A61B5/0205 , A61B5/00 , G16H40/67
CPC classification number: G16H50/20 , G16H20/17 , A61B5/02055 , A61B5/7475 , G16H40/67
Abstract: A method (500) for managing nausea includes receiving, from one or more monitoring devices (200), patient parameter data (212) of a patient (10). The patient parameter data is collected by the one or more monitoring devices. The method also includes determining, based on the patient parameter data of the patient, whether the patient is experiencing or about to experience an episode of nausea. When the patient is experiencing or about to experience an episode of nausea, the method also includes communicating one or more therapy signals (302, 304, 306, 308) to a receiver device (12, 21, 400) in communication with the computing device.
-
-
-
-
-
-
-
-
-